Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q2 2015 · 10-Q
Revenue$5.29M$5.29M+39.1% vs Q2 2014 Net Income-$6.25M-$6.25MN/M vs Q2 2014 EPS Diluted-$0.09-$0.09N/M vs Q2 2014 Operating Income-$15,120,093N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,667,734N/M Margins · derivedOperating margin-286.0%−18.9 pt vs Q2 2014
Net margin-118.2%+163.6 pt vs Q2 2014
ended Jun 30, 2015 · filed Aug 10, 2015 · 41 d after period end